Competition Grows In Claudin18.2 As AstraZeneca Seals Antibody Conjugate Deal

Chasing Astellas In Gastric Cancer

Already a major player in the field thanks to Enhertu, AstraZeneca is doubling down in gastric cancer with the new antibody-drug conjugate deal with China’s KYM Biosciences.

AstraZeneca
• Source: Shutterstock

The search for promising new targets in cancer immunotherapy is one of the top priorities in biopharma and Claudin18.2’s potential in gastric cancer has become one of the hottest emerging areas.

That promise has been highlighted by a new deal between AstraZeneca with Chinese biotech KYM Biosciences to develop CMG901,...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip